원내
Safety and efficacy in pediatric patients <3y of age have not been established
HIV-infected pediatric patients with no Darunavir resistance associated substitutions 35 mg/kg PO q24h + Ritonavir 7 mg/kg PO q24h
Treatment-experienced HIV-infected pediatric patients with ≥1 Darunavir resistance associated substitution 20 mg/kg PO q12h + Ritonavir 3 mg/kg PO q12h
No renal dose adjustment